Direct Healthcare Professional Communication (DHPC) on Natpar 100 microgram/dose powder and solvent for solution for injection of the company Takeda: Discontinuation of manufacturing at the end of 2024 and update on shortage of 100 microgram/dose
2022.10.07
Active substance: Parathyroid hormone
Takeda informs about the discontinuation of the production of all dose strengths of Natpar until the end of 2024 due to unresolved manufacturing challenges. This means that Natpar will be withdrawn from the global market. Beyond 2024, Takeda intends to supply available doses until inventory is depleted or expired. The supply shortage for the 100 microgram dose strength will continue until the discontinuation of manufacturing. To deal with the supply shortage, the company has published the recommendations described in the DHPC. Healthcare professionals are advised not to initiate any new patients on any strength on Natpar.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN